基亞生物科技股份有限公司/Medigen Biotechnology Corp.
基亞生物科技股份有限公司/Medigen Biotechnology Corp.
  • About
    • Company Overview
    • Our Vision
    • Corporate Structure
    • Corporate Governance
      • Board of Directors
      • Remuneration Committee
      • Organization and Operation of Internal Audit
      • Corporate Governance Status
      • Corporate Regulations
      • Corporate Social Responsibility Status
    • Management
    • Careers
    • Subsidiaries
      • Medigen Vaccine Biologics Corporation
      • TBG Diagnostics Limited
      • Winston Medical & Biotech Group
  • Cell Therapy
    • MAGICELLl–NK (Natural killer cells)
    • MAGICELL®-GDT​(T cells)
    • GTP certificated cell processing facility
    • Cell Therapy Cooperation Agency
    • Cell Therapy Regulation in Taiwan
  • COVID-19
  • CLINICAL TRIALS
    • Product Pipelines
    • NK CELL (MAGICELL-NK)
    • OBP-301 (Telomelysin)​
  • NEWS
    • Material Information
      • 2025
      • 2024
      • 2023
      • 2021
    • Financial Statement
    • Shareholder Services
  • Investors
    • Financial Statements
      • Monthly Revenue Statement
      • Quarterly and Annual Report
    • Shareholder Services
      • Share Price
      • Shareholder Meeting Document
    • Contact Information
    • Stakeholders
  • Language
    • 中文 (繁)
    • English
    • 中文 (简)

Blog

Home | NEWS | TBG Diagnostics Limited listed on Australian Securities Exchange (ASX) on February 3, 2016.

TBG Diagnostics Limited listed on Australian Securities Exchange (ASX) on February 3, 2016.

0
By Teddy
2016-03-16
NEWS


TBG Inc., the subsidiary of Medigen Biotechnology, owned 51.76% stake of TBG Diagnostics Limited (formerly Progen Pharmaceuticals Limited) after stock swap. TBG Diagnostics Limited(TDL) is now listed on Australian Securities Exchange (ASX) as of February 3, 2016.

Related news (in Chinese):
1.Yahoo Stock

  • News
  • Financial Statement
  • Shareholder Services
previous postnext post
14F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan (R.O.C)‧Copyright© 2021-2025 Medigen Biotechnology Corp. All rights reserved.